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Note
Genome-Edited Animals Are Not Transgenic
Animals: Moving towards Responsible Research
and Innovation with New Biotechnologies
Yvie Yao*
INTRODUCTION
In November 2018, a Chinese scientist announced that he
was the first person to use the gene-editing technique, CRISPRCas9, to create a genome-edited baby resistant to HIV, small
pox, and malaria.1 This alarming announcement immediately
received criticism and concern from scientists around the globe.2
Some of them questioned the technique of applying CRISPRCas9 to human embryos because of unknown gene-editing risks.3
For example, knocking out the gene that controls HIV might
render a person susceptible for West Nile Virus.4 Some other
scientists challenged the ethical implications of this move to
produce “designer babies.”5 Marcy Darnovsky, executive director
of the Center for Genetics and Society, lamented that “this

© 2019 Yvie Yao
* J.D. Candidate, 2020, University of Minnesota Law School
1. See Rob Stein, Chinese Scientist Says He’s First to Create Genetically
Modified Babies Using CRISPR, NPR (Nov. 26, 2018, 5:02 AM),
https://www.npr.org/sections/health-shots/2018/11/26/670752865/chinesescientist-says-hes-first-to-genetically-edit-babies.
2. See, e.g., Antonio Regalado, Chinese Scientists Are Creating CRISPR
Babies,
MIT
TECH.
REV.
(Nov.
25,
2018),
https://www.technologyreview.com/s/612458/exclusive-chinese-scientists-arecreating-crispr-babies/ (noting that some scientists called the undertaking
cause for “regret and concern over the fact that gene editing—a powerful and
useful technique—was put to use in a setting where it was unnecessary.”).
3. See Stein, supra note 11 (noting that applying CRISPR-Cas9 to
embryos might introduce unknown, new diseases that could be passed down for
generations).
4. See id.
5. See id.
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amounts to unethical and reckless experimentation on human
beings, and a grave abuse of human rights.”6
CRISPR-Cas9 is a groundbreaking gene-editing technology
that enables scientists to make precise changes in DNA more
easily, quickly, and economically.7 Scientists can now insert or
delete certain genes at a specific site with the aid of CRISPRCas9.8 As a result, this technology raises high hopes among
scientists for major breakthroughs in all applications.9
Meanwhile, the government and other experts assert that the
current regulatory landscape in the United States over genomeedited products with new biotechnologies like CRISPR-Cas9—
the Coordinated Framework for the Regulation of
Biotechnology—may be inadequate to manage the risks
associated with gene-editing techniques and their impacts on the
environment and human health because existing regulations
cannot keep up with the rapidly growing biotechnologies.10
Although the public does not yet need to be concerned with
the application of CRISPR-like techniques on human embryos in
the United States,11 they will likely see CRISPR-edited food on

6. Press Release, Ctr. for Genetics & Soc’y, Claim of Genetically Modified
Babies: If True, a Grave Abuse of Human Rights (No v. 26, 2018),
https://www.geneticsandsociety.org/press-statement/claim-geneticallymodified-babies-if-true-grave-abuse-human-rights.
7. See Henry T. Greely, Are We Ready for Genetically Modified Animals,
WORLD
ECON.
FORUM
(Jan.
19,
2016),
https://www.weforum.org/agenda/2016/01/are-we-ready-for-geneticallymodified-animals/. Though this Note primarily focuses on CRISPR-Cas9, the
discussion also applies to other CRISPR-like gene-editing technologies such as
ZFNs and TALENs. See Daniel F. Voytas & Caixia Gao, Precision Genome
Engineering and Agriculture: Opportunities and Regulatory Challenges, 12
PLOS BIOLOGY 1, 2 (2014).
8. See Tracey Tomlinson, A CRISPR Future for Gene-Editing Regulation:
A Proposal for an Updated Biotechnology Regulatory System in an Era of
Human Genomic Editing, 87 FORDHAM L. REV. 437, 445–46 (2018).
9. See Stein, supra note 1.
10. See generally MARCY E. GALLO ET AL., ADVANCED GENE EDITING:
CRISPR-CAS9 (2018) (finding that “[r]egulatory gaps may lead to increased
uncertainty that could slow down the development of future biotechnology
products or result in a loss of public confidence in regulators.”).
11. See Julia Belluz, How Soon Will CRISPR Gene-edited Babies Come to
the
US?
VOX
(Dec.
6,
2018),
https://www.vox.com/science-andhealth/2018/12/6/18126338/crispr-babies-china-gene-editing
(noting
that
genetically-modified embryos are prohibited in the U.S. and offenders might
face jail time and a $100,000 fine).
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their plates in the very near future.12 The first of these genomeedited crops—Cibus Canola—went on the market in 2018,13 with
more coming such as TALEN-edited soybeans that contain no
trans fats.14 Though genome-edited animals have not yet been
approved for human consumption, a transgenic salmon—
AquAdvantage Salmon—using the recombinant DNA
technology has already been approved by the Food and Drug
Administration (FDA).15 Some scientists and environmental
groups have raised ethical questions about the unintended
ecological consequences of introducing a genetically modified
organism into an open environment.16
Traditionally, the FDA has regulated genetically engineered
animals for consumption under the new animal drug provisions
of the Federal Food, Drug and Cosmetic Act (FD&C Act).17 With
its pronouncement of guidance #187 on intentionally altered
genomic DNAs in 2017, the FDA also indicates that it inclines to
regulate genome-edited animals with CRISPR-like technologies
12. See Michael Le Page, The Second Great Food War: Battle Lines Are
Being Drawn Over Whether Crops and Animals Modified with CRISPR Gene
Editing Can Make It onto Supermarket Shelves, 239 NEW SCIENTIST 22 (2018)
(“What we eat could be about to undergo a big change.”).
13. See Frank Vinluan, Cibus Raises $70M for Marketing of Gene-edited
Canola, More R&D, XCONOMY (June 27, 2018), https://xconomy.com/sandiego/2018/06/27/cibus-raises-70m-for-marketing-of-gene-edited-canola-morerd/ (reporting that sales of Cibus’ gene-edited canola went up).
14. See Caitlin Dewey, The Future of Food: Scientists Have Found a Fast
and Cheap Way to Edit Your Food’s DNA, WASH. POST (Aug. 11, 2018),
https://www.washingtonpost.com/news/business/wp/2018/08/11/feature/thefuture-of-food-scientists-have-found-a-fast-and-cheap-way-to-edit-your-ediblesdna/?utm_term=.be6680777901.
15. See generally U.S. FOOD & DRUG ADMIN., AN OVERVIEW OF ATLANTIC
SALMON, ITS NATURAL HISTORY, AQUACULTURE, AND GENETIC ENGINEERING
(updated
Mar.
20,
2015),
https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Veteri
naryMedicineAdvisoryCommittee/ucm222635.htm
[https://wayback.archiveit.org/7993/20170404230805/https://www.fda.gov/AdvisoryCommittees/Commit
teesMeetingMaterials/VeterinaryMedicineAdvisoryCommittee/ucm222635.ht
m] [hereinafter USDA].
16. See Ocean Conservancy, et al., Citizen Petition Regarding AquaBounty
Technologies’ Application for Approval of Genetically Engineered Salmon (May
25, 2011), https://www.regulations.gov/document?D=FDA-2011-P-0448-0001.
17. In this Note, “genetically engineered animal” is a catchall phrase that
refers to animals modified by rDNA techniques or other methods involving
inserting DNA from one organism’s genome into another organism’s cell directly
without any precise modification. See Guidance for Industry on Regulation of
Genetically Engineered Animals Containing Heritable recombinant DNA
Constructs, 74 FED. REG. 3057, 3057 (Jan. 16, 2009).
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under the same provisions.18 Yet, this guidance was not well
received by various stakeholders.19 Scientists and developers
worry that the FDA’s interpretation of altered genomic DNAs as
animal drugs can stunt innovation of biotechnologies that will
bring numerous benefits to the society.20 In the meantime,
nonprofits and other organizations disagree with the FDA’s
approach to treating genome-edited animals the same as
transgenic animals, when in fact they pose different levels of
risk.21
Therefore, the questions for this Note are whether the FDA’s
updated draft #187 provides legally sound mechanism for agency
oversight of genome-edited animals and whether other
regulatory pathways exist for agency oversight of genome-edited
animals with new CRISPR-like biotechnologies under the
current regulatory framework. Part I explains CRISPR-Cas9
and other precision gene-editing technologies, the history of the
application of biotechnology on animals and the current
development of genome-edited animals, U.S. regulatory
framework on biotechnology, and the FDA’s draft guidance #187.
Part II discusses how the FDA’s interpretation of altered
genomic DNAs as animal drugs has exceeded its vested
authority by Congress under existing statutes, how the FDA’s
approach deviates from the product-oriented regulatory
approach, and how the FDA’s issuance of the guidance document
is inadequate to address biotechnology products that affect the
environment and human health. Part III explores alternative

18. See Regulation of Intentionally Altered Genomic DNA in Animals Draft
Guidance, 82 FED. REG. 6561 (Jan. 19, 2017).
19. Cf., e.g., Consumers Union, Comment Letter on the Food and Drug
Administration’s Draft Guidance for Industry #187 “Regulation of Intentionally
Altered
Genomic
DNA
in
Animals”
(June
19,
2017),
https://www.regulations.gov/document?D=FDA-2008-D-0394-0431.
20. See, e.g., Info. Tech. & Innovation Found., Comment Letter on the Food
and Drug Administration’s Draft Guidance for Industry #187 “Regulation of
Intentionally Altered Genomic DNA in Animals” (Apr. 11, 2017),
https://www.regulations.gov/document?D=FDA-2008-D-0394-0331.
21. See, e.g., Ctr. for Food Safety, Comment Letter on The Food and Drug
Administration’s Draft Guidance for Industry #187 “Regulation of Intentionally
Altered
Genomic
DNA
in
Animals”
(June
19,
2017),
https://www.regulations.gov/document?D=FDA-2008-D-0394-0427; see also
Nat’l Ass’n of St. Dep’t of Agric., Comment Letter on the Food and Drug
Administration’s Draft Guidance for Industry #187 “Regulation of Intentionally
Altered
Genomic
DNA
in
Animals”
(June
19,
2017),
https://www.regulations.gov/document?D=FDA-2008-D-0394-0409.
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pathways for agency oversight of genome-edited animals under
the existing statutes and proposes that the White House updates
the Coordinated Framework to incorporate the Responsible
Research and Innovation (RRI) principle so as to address the risk
of new biotechnological products while fostering public welfareoriented responsible innovation with societal acceptability.
Notably, in focusing on the FDA’s draft guidance to regulate
intentionally altered genomic DNA, this Note is not intended to
disrespect the FDA and its approach to protect the public health
and food safety. Instead, this Note, using the FDA’s guidance as
an illustration, highlights the shortfalls of the current
regulatory framework and its inability to adapt to the disruptive
nature of technological development. In an environment of what
some regulation scholars call “global innovation arbitrage,”22 the
answer to the “what is the right regulatory approach?” question
is key to keep the U.S. competitive in biotechnological innovation
while protecting citizens and human interest.
I.

BACKGROUND

This Part of the Note provides background information on
CRISPR-Cas9 as an illustration of precision gene-editing
technologies, a brief survey of the development of animal
biotechnologies, current regulatory structures for biotechnology
in the United States, particularly the existing regulations over
genetically engineered animals, and the FDA’s attempt to cover
genome-edited animals under the existing statutes through
guidance #187. The background information of Part I will
facilitate an understanding of the technical analysis of guidance
#187 and shed light on reasons as to why the current regulatory
framework cannot keep up with disruptive technologies like
CRISPR-Cas9 which would be discussed later in detail.
A. WHAT IS CRISPR?
CRISPR, an acronym for Clustered Regularly Interspaced
Short Palindromic Repeat, is an “organization of short, partially
22. See Adam Thierer, Global Innovation Arbitrage: Export Controls
Edition,
THE
TECH.
LIBERATION
FRONT
(Jan.
2,
2019),
https://techliberation.com/2019/01/02/global-innovation-arbitrage-exportcontrols-edition/ (defining global innovation arbitrage as the “idea that
innovators can, and will with increasingly regularity, move to those
jurisdictions that provide a legal and regulatory environment more hospitable
to entrepreneurial activity.”).
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palindromic repeated DNA sequences” naturally found in
bacteria.23 First discovered in 1987, CRISPR was shown to be a
successful bacterial defense mechanism against viruses twenty
years later.24 CRISPR is made up of two parts: repeats that are
short sequences of DNA, and unidentical spacers that connect
these repeats.25 Also found within the bacterium are CRISPRassociated genes, known as Cas genes, which make Cas9
proteins that are able to unwind and cleave DNA.26
When a virus attacks a bacterial cell, some segments of the
viral DNA will be copied and inserted as a new spacer into the
existing bacterial CRISPR sequences.27 Immediately, the
CRISPR sequences that includes this new spacer from the viral
DNA undergo a process of transcription—copying the doublechain helix structured DNA into a single-chain RNA.28 The short
segments of this long RNA transcribed from the original
CRISPR sequences are CRISPR RNAs (crRNAs).29 Should the
same virus attack again, the Cas genes will be triggered to create
Cas9 proteins. Then, the crRNAs will guide these Cas9 proteins
to the invading virus because the crRNAs, with copies of the
corresponding viral DNA, are able to match the viral genome.30
These Cas9 proteins will then destroy the viral genome by
unwinding its DNA and cutting up any DNA sequence that
matches the crRNA sequence.31
In the field of genome editing, CRISPR refers to one of the
many gene-editing technologies that enable scientists to make
precise cuts along a cell’s genome.32 The CRISPR system consists
23. See Ekaterina Pak, CRISPR: A Game-Changing Genetic Engineering
Technique, HARV. U. GRADUATE SCH. OF ARTS & SCI. (July 31, 2014),
http://sitn.hms.harvard.edu/flash/2014/crispr-a-game-changing-geneticengineering-technique/.
24. 24.
See generally GALLO ET AL., supra note 10, at 32 (2017)
(providing a chronology of discoveries and milestones in the development of
CRISPR-Cas9).
25. See Bozeman Science, What Is CRISPR?, YOUTUBE (Feb. 18, 2016),
https://www.youtube.com/watch?v=MnYppmstxIs.
26. See id. Cas proteins convert chemical energy into mechanical forces in
response to specific stimuli. Pak, supra note 23.
27. See Pak, supra note 23.
28. See id.
29. See id.
30. See Bozeman Science, supra note 25.
31. See id.
32. See Tomlinson, supra note 8, at 443 (“CRISPR is used as a catchall term
for systems that enable researchers to program the CRISPR molecule to make
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of two components: the Cas9 protein and a guide RNA that can
recognize the sequence of DNA to be edited.33 Scientists are able
to create guide RNAs that match specific DNA sequences to be
edited in a cell, just like how CRISPR in a bacterium generates
crRNAs.34 Scientists then attach these artificially created guide
RNAs to the DNA-cutting protein Cas9 and introduce this
complex into the target cell.35 The guide RNAs will direct the
enzyme Cas9 to the targeting DNA sequence at a specific site,
allowing it to unwind the double helixes and subsequently
matching to the single-stranded DNA sequence.36 When the
match completes, Cas9 will cut the targeted DNA sequence; once
the host DNA is broken, the gene will be successfully inactivated
or deleted.37 Scientists can also add a new RNA sequence to
where the host DNA is cut; by doing this, they successfully add
genetic material to the target cell.38 After these intentional edits,
scientists rely on a cell’s own ability to repair its DNA
sequence.39 With the CRISPR-Cas9 system, scientists can finally
edit the existing genome by deleting or inserting DNA sequences
at a precise location.40

precise cuts along a cell’s genome.”). See Voytas & Gao, supra note 7, at 2
(introducing other types of genome-editing technologies that are similar to
CRISPR which include engineered homing endonucleases or meganucleases,
zinc finger nucleases (ZFNs), and transcription activator-like effector nucleases
(TALENs)).
33. See GALLO ET AL., supra note 10, at 2–3 (explaining how the CRISPRCas9 system functions).
34. See id.
35. See id.
36. See id.
37. See Evita V. Grant, FDA Regulation of Clinical Applications of
CRISPR-CAS Gene-Editing Technology, 71 FOOD & DRUG L.J. 608, 611 (2016)
(explaining that the CRISPR-Cas system can “recognize and cleave a specific
sequence of DNA, allow[ing] it to be developed into artificial restriction enzymes
that can be used to alter specific sites of DNA in any organism.”).
38. See id.
39. See U.C. BERKELEY, DNA Repair After CRISPR Cutting Not at All What
People Think, PHYS.ORG (Jul. 30, 2018), https://phys.org/news/2018-07-dnacrispr-people-thought.html (explaining two types of repair: non-homologous
end-joining repair and homology-directed repair).
40. See Tomlinson, supra note 8, at 445–46 (claiming that CRISPR is the
“most advanced gene-editing technology currently available” that enables
“scientists to edit the human genome in previously impossible ways.”).
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B. CRISPR-LIKE TECHNOLOGIES ARE DIFFERENT FROM
TRANSGENESIS TECHNIQUES
This newly evolved CRISPR-Cas9 system, along with other
gene-editing technologies,41 differs from transgenesis which
directly inserts a copy of genetic material with a specific trait
from a donor organism into a cell of a recipient organism.42
Transgenesis, however, does not control the site in the genome
where the inserted material will end up and can result in
random consequences.43 Unlike traditional genetic engineering
with transgenic techniques, scientists can precisely edit a single
sequence of the genome at a very specific site with CRISPRCas9.44 Thus, CRISPR-Cas9 is at least 10 times more accurate
and predictable.45 It can also democratize biotechnology because
anyone with basic knowledge and skills in molecular biology can,
theoretically, perform a CRISPR cutting.46
Furthermore, CRISPR-Cas9 is often viewed less as an
artificial process but a mechanism “mimicking a natural
mutation.”47 This is because gene-editing does not require the
transfer of DNA from one organism to another but capitalizes on
a cell’s natural defense mechanism to induce “a specific change

41. See Voytas & Gao, supra note 32 and accompanying text.
42. See Leslie Pray, Recombinant DNA Technology and Transgenic
Animals, 1 NATURE EDUC. 51 (2008) (discussing inserting foreign DNA into a
new host cell).
43. See GMO Answers, How Are GMOs Created? | The Hawaiian Rainbow
Papaya Story, YOUTUBE (Aug. 2, 2013), https://www.youtube.com/watch?v=2GyUuiqIZ0&t=234s.
44. See Ken Kingery, What Is CRISPR, and How Has It Changed Genetic
Research?,
WORLD
ECON.
FORUM
(Oct.
30,
2015),
https://www.weforum.org/agenda/2015/10/what-is-crispr-and-how-has-itchanged-genetic-research/ (“The primary advantage of CRISPR over previous
technologies is the ability to use a genetic scalpel rather than a
sledgehammer[.]”); see also Greg Licholai, Is CRISPR Worth the Risk?, YALE
INSIGHTS (Aug. 21, 2018), https://insights.som.yale.edu/insights/is-crisprworth-the-risk (“What was previously attempted with gene editing was . . . kind
of like trying to edit a book by only being able to rip out a page at a time and
transfer a page at a time . . . . [T]his technology . . . literally comes down to the
individual letters.”).
45. See Greely, supra note 7 (“DNA editing had been done in laboratories
for about 40 years, but CRISPR/Cas9 is at least 10 times more accurate, faster,
easier and less expensive.”).
46. See Grant, supra note 37, at 626–27 (describing CRISPR as accessible,
easy to use and affordable).
47. Ann Bruce, Genome Edited Animals: Learning from GM Crops?, 26
TRANSGENIC RES. 385, 389 (2017).
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at a precise location in the genome.”48 Despite their accuracy and
accessibility, CRISPR-like technologies could potentially result
in off-target effects when the Cas9 enzyme snips at similar nontarget sites.49 Scientists have developed various strategies to
contain such effects.50 This Note, however, will not go into
details discussing various shortfalls of CRISPR-like technologies
and how scientists have adopted measures to tackle these
problems.51
C. HISTORICAL OVERVIEW OF GENETICALLY ENGINEERED
ANIMALS BEFORE CRISPR-LIKE TECHNOLOGIES
Looking back at the development of biotechnology, it is not
hard to find the application of biotechnology on animals; in fact,
animal biotechnology has been around for centuries.52 Before the
late nineteenth century, human-directed breeding was the
dominant method for the selection of animals that match
particular production traits and purposes suited to a specific
climate.53 In the next fifty years, the farm animal industry
witnessed a growing array of reproductive biotechnologies, such
48. See id. at 391 (arguing that “genome editing does not transgress species
barriers” but does “require a deliberate intervention that is outside natural
mutation.”).
49. See generally Ellen Shrock & Marc Güell, CRISPR in Animals and
Animal Models, in 152 PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL
SCIENCE 1, 97 (Raúl Torres-Ruiz & Sandra Rodriguez-Perales eds., 2017)
(discussing that off-target effects might cause chromosomal deletions,
inversions, or translocations).
50. See Wenfang Tan, et al., Gene Targeting, Genome Editing: From Dolly
to Editors, 25 TRANSGENIC RES. 273, 283 (2016) (providing examples to control
off-site effects such as masking Cas9 with a fusion peptide, preventing activity
until cleaved by a small molecule, expanding the TALEN RDV repertoire,
dimerizing the editing enzyme, etc.).
51. Excellent articles in the last few years have detailed the shortfalls of
CRISPR-Cas9. See Michael Kosicki, Kärt Tomberg & Allan Bradley, Repair of
Double-Strand Breaks Induced by CRISPR-Cas9 Leads to Large Deletions and
Complex Rearrangements, 36 NATURE BIOTECHNOLOGY 765 (2018); see also
Heidi Ledford, CRISPR Gene Editing Produces Unwanted DNA Deletions,
NATURE (Jul. 16, 2018), https://www.nature.com/articles/d41586-018-05736-3.
52. See Heiner Niemann & Bob Seamark, The Evolution of Farm Animal
Biotechnology,
in
ANIMAL
BIOTECHNOLOGY
1:
REPRODUCTIVE
BIOTECHNOLOGIES 1, 1–8 (Heiner Niemann & Christine Wrenzycki eds., 2018)
(discussing “Domestication”, “Systematic Breeding”, and “Scientifically-based
Breeding” as forms of animal biotechnology).
53. See id. at 3 (“[H]uman-directed breeding results in the abundance of
great phenotypic and genetic variation in domesticated animals including, for
example, the more than 3,000 cattle and 1,300 pig breeds”).
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as artificial insemination.54 Artificial insemination has replaced
traditional breeding methods for breeders and “remain[ed] the
primary method . . . around the globe [] to improve the genetic
quality of their animals . . . .”55
In the next twenty years, researchers have applied this
DNA analysis to animal breeding, using quantitative trait loci
(QTL) to identify causal mutations for specific traits.56 Soon, a
new era in animal breeding began with the creation of the first
transgenic pigs and sheep.57 Transgenesis can be achieved by
microinjection of a foreign DNA into an oocyte—an immature
egg cell of the animal ovary—shortly after fertilization.58
Transgenesis, nevertheless, faced a few limitations, the primary
one being that the introduced DNA could only be integrated
randomly in the recipient genome.59 As of today, there is already

54. See id. at 5 (showcasing that under these emerging reproductive
biotechnologies, genetics has been applied to animal breeding, which has helped
identify inheritable chemical or molecular markers that could be used to guide
breeding technologies and promote genetic change in economically important
productive traits).
55. See id. at 10 (“[Artificial Insemination] is employed in more than 90%
of all sexually mature female dairy cattle in countries with well-advanced
breeding programs . . . . [t]he adoption of [artificial insemination] for use with
low unit cost animals such as sheep and goats is less widespread but is still
employed in the breeding of greater than 3.3 million sheep and 0.5 million goats
annually”).
56. See id. at 7–8 (finding that the QTL strategy was succeeded by markerassisted selection which includes the detection of several QTLs, followed by
identification of the gene which causes the respective mutation and finally the
increase of the frequency of the favorable allele by selection).
57. See Niemann & Seamark, supra note 52, at 19 (“[I]ntroducing new and
functional genetic material into the germline of laboratory rodents heralded a
new era in animal breeding.”). See generally Götz Laible, Production of
Transgenic Livestock: Overview of Transgenic Technologies, in ANIMAL
TECHNOLOGY 2: EMERGING BREEDING TECHNOLOGIES 95, 95–113 (Heiner
Niemann & Christine Wrenzycki eds., 2018) (discussing transgenic livestock).
58. See Laible, supra note 57, 95–113 (introducing two types of transgenic
technologies: the embryo-mediated approach refers to the introduction of the
genetic modification into an embryo whereas the cell-mediated approach refers
to the introduction of genetic information into a cell which “is subsequently used
to generate an entire animal based on the genetics of this cell.”).
59. Niemann & Seamark, supra note 52, at 19. See Laible, supra note 57,
at 101–02 (finding that “only 70% of transgenic founder animals were able to
transmit the transgene through the germline to the next generation” and that
the process is inefficient and very expensive).
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one transgenic animal approved for human consumption in the
United States—AquAdvantage Salmon.60
D. EMERGING APPLICATIONS OF CRISPR-LIKE TECHNOLOGIES
ON ANIMALS
The CRISPR-Cas9 system has overcome the many
limitations transgenesis faced and has been used to create a
wide variety of genome-edited animals, such as pigs, cattle,
goats, and sheep.61 Unlike transgenesis which might lead to
random consequences from the combination of the donor
organism’s DNA with the recipient organism’s cell, CRISPRCas9 is able to edit an animal’s genome in a precise manner to
obtain a targeted trait.62 Consequently, genome-edited animals
created from CRISPR-like technologies play an important role in
“highly diverse areas such as food improvement, disease
resistance, and human disease models.”63 For instance,
AgGenetics has engineered Angus cows to produce a certain type
of hair that will allow them to adapt to warmer climates and
thus increase Angus beef’s yields.64 Recombinetics has also geneedited a hornless breed of cattle, freeing it from using hot irons
to burn off horns during food processing and significantly
improving animal welfare.65 Moreover, CRISPR-Cas9 has also

60. See Heidi Ledford, Transgenic Salmon Leaps to the Dinner Table, 527
NATURE 417 (2015). See generally, USDA, supra note 15 (illustrating that
AquAdvantage fish produce extra growth hormone which allows them to grow
to market size in eighteen months rather than the usual three years).
61. See generally Shrock & Güell, supra note 49, at 98–105 (outlining three
methods of using the CRISPR-Cas9 system on animals); Tan, supra note 50, at
277 (listing all genome-edited animals in a table); see Gavin J. Knott & Jennifer
A. Doudna, CRISPR-Cas Guides the Future of Genetic Engineering, 361 SCI.
866, 867 (2018) (discussing applications of CRISPR to biomedical and clinical
research, such as engineering T cells as a prelude to developing advanced
immunotherapies to target cancers and targeting the genetic basis for sickle cell
disease); see GALLO, supra note 24, at 20 (explaining that CRISPR has also been
widely applied to agricultural development, such as better plant-pest control,
new and enhanced nutritional characteristics, and plant varieties that could be
grown on marginal lands or in poor quality soils).
62. See supra Section I.B.
63. Bjoern Petersen, DNA Nucleases and their Use in Livestock Production,
in ANIMAL BIOTECHNOLOGY 2: REPRODUCTIVE BIOTECHNOLOGIES 123, 124
(Heiner Niemann & Christine Wrenzycki eds., 2018).
64. See Shrock & Güell, supra note 49, at 104.
65. See id. (providing additional examples such as genetically modified
chickens which produce non-allergen eggs, pigs resistant to the Porcine
Reproductive and Respiratory Syndrome Virus, and cattle are resistant to

410

MINN. J.L. SCI. & TECH.

[Vol. 20

been used to produce genome-edited pets that contain custom
traits.66 Overall, CRISPR-Cas9 has significantly accelerated the
creation of animals with novel traits that may be beneficial for
agricultural production and animal health.67
E. CURRENT REGULATORY FRAMEWORK FOR BIOTECHNOLOGY
IN THE U.S.
The federal government has a long history of regulating
biotechnology. It first came up with a set of research guidelines
in the 1970s in response to the emerging recombinant DNA
research for transgenesis technologies.68 In the next eight years,
Congress made many attempts to enact a unified biotechnology
legislation to address the emerging genetic manipulation
techniques.69 In 1984, the White House Cabinet Council on
bovine tuberculosis). See generally Adam Shriver & Emilie McConnachie,
Genetically Modifying Livestock for Improved Welfare: A Path Forward, 31 J.
AGRIC. ENV’T ETHICS 161 (2018) (arguing that modern biotechnologies improve
animal welfare).
66. See Shrock & Güell, supra note 49, at 105 (providing examples of very
small pigs as pets and dogs with improved running ability).
67. See, e.g., id. at 101 (“The uses of CRISPR–Cas9 for animal genome
engineering include . . . the inactivation or alteration of genes in model animals
in order to elucidate the functions of these genes . . . the production of animal
models of human disease to study disease progression in a controlled manner
and evaluate potential therapies . . . and the use of genetically modified animals
for industrial, pharmaceutical, and biotechnological production”); Bruce, supra
note 47, at 387–88; Zahra Meghani & Jennifer Kuzma, Regulating Animals with
Gene Drive Systems: Lessons from the Regulatory Assessment of a Genetically
Engineered Mosquito, 5 J. RESPONSIBLE INNOVATION 203 (2018) (discussing
gene drives); George Washington University Regulatory Studies Center,
Comment Letter on The Food and Drug Administration’s Draft Guidance for
Industry #187 “Regulation of Intentionally Altered Genomic DNA in Animals”
(June 19, 2017), https://www.regulations.gov/document?D=FDA-2008-D-03940416 (listing CRISPR projects that involve resurrecting lost species, protecting
extremely endangered species, increasing agricultural productivity and
controlling human disease dependent on wild animal hosts); Veronique
Greenwood, How CRISPR Is Spreading Through the Animal Kingdom,
PBS.ORG (May 23, 2018), https://www.pbs.org/wgbh/nova/article/crispranimals/.
68. See NAT’L ACAD. OF SCI., ENG’G, AND MED., PREPARING FOR FUTURE
PRODUCTS OF BIOTECHNOLOGY 69 (2017) (explaining that the National
Institutes of Health published a set of research guidelines in 1976 as the
prototype of the federal regulatory framework, applied to all research with
recombinant or synthetic nucleic acid molecules).
69. See WHITE HOUSE, MODERNIZING THE REGULATORY SYSTEM FOR
BIOTECHNOLOGY PRODUCTS: FINAL VERSION OF THE 2017 UPDATE TO THE
COORDINATED FRAMEWORK FOR THE REGULATION OF BIOTECHNOLOGY 3 (2017)
(explaining that enhanced characteristics of food, manufactured food, waste
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Natural Resources and the Environment formed a working
group on biotechnology which proposed a coordinated framework
to address products developed from new technologies.70
In 1986, the White House issued the nation’s first regulatory
document about genetically engineered products, Coordinated
Framework on the Regulation of Biotechnology (Coordinated
Framework), which clarified the regulatory authority and
responsibility of each federal agency regarding products derived
from new biotechnologies.71 The framework identified a lead
agency among the agencies responsible for regulation of a
specific product category or use: the FDA regulates the safety of
all food and cosmetic products sold for human use; the
Department of Agriculture (USDA) regulates the production and
marketing of products grown on farms; and the Environment
Protection Agency (EPA) regulates actual and potential threats
to human health resulting from disruption of the environment.72
The Coordinated Framework also established three
essential tenets: (1) U.S. regulatory policy over biotechnological
products would be product-based instead of process-based;73 (2)
only regulation grounded in verifiable scientific risks would be
tolerated;74 (3) existing statutes are sufficient to review new
products, meaning that statutes enacted before this framework

disposal, medicine and pesticides rely upon new techniques such as
recombinant DNA, recombinant RNA, and cell fusion).
70. See id. at 70 (orchestrating the biotechnology-related responsibilities of
multiple federal agencies).
71. Executive Office of the President, Coordinated Framework for
Regulation of Biotechnology, 51 FED. REG. 23302, at 23303 (June 26, 1986).
72. WHITE HOUSE, supra note 69, at 28 n.77; Edward L. Rubin & Joanna
K. Sax, Administrative Guidance and Genetically Modified Food, 60 ARIZ. L.
REV. 539, 554 (2018).
73. See Zahra Meghani, Genetically Engineered Animals, Drugs, and
Neoliberalism: The Need for a New Biotechnology Regulatory Policy Framework,
30 J. AGRIC. ENV’T ETHICS 715, 733 (2017) (“Regulation by the FDA must be
based on the rational and scientific evaluation of products, and not on a priori
assumptions about certain processes.”); Rubin & Sax, supra note 72, at 555
(focusing on the characteristics and risk posed by the introduction, rather than
on the process by which a product is created).
74. Eric E. Williams, CRISPR: Redefining GMOs—One Edit at a Time, 39
U. ARK. LITTLE ROCK L. REV. 437, 451 (2017). See generally NAT’L ACAD. OF SCI.,
ENG’G, AND MED., supra note 68, at 69 (“Regulatory risk
assessment . . . [identifies] possible causes of harm . . . the relationship between
exposure to the harm and the probability of the adverse effect . . . the extent of
human or environmental exposure to the harm, and . . . the probability of the
harm occurring and the magnitude of the possible harm[.]”).
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were interpreted to cover biotechnology.75 Under this
framework, the federal government sought to “achieve a balance
between regulation adequate to ensure the protection of health
and the environment while maintaining sufficient regulatory
flexibility to avoid impeding innovation.”76 In 1992, the
Coordinated Framework was updated to reaffirm a scientific,
risk-based, and product-based approach consistent with the
1986 Coordinated Framework.77
Almost twenty years later, the White House updated the
Coordinated Framework in 2017 in response to the accelerating
development and application of precise gene-editing
biotechnologies.78 In the past decade, there were growing
concerns regarding whether products developed using new
technologies such as CRISPR-Cas9 would fall outside the scope
of existing regulations and what factors should be considered to
assess risks.79 Thus, the 2017 update attempted to clarify: (1)
what biotechnology product areas are regulated; (2) what roles
each agency plays for different product areas; (3) how agencies
communicate and coordinate with each other; and (4) what
reviewing and updating mechanism each agency should adopt.80
This update reaffirmed the tenets established under the 1986
Coordinated Framework that regulations should be product-

75. See Meghani, supra note 73, at 733 (arguing that the working group
chose existing statutes because of the considerations of “immediate regulatory
protection and certainty” for the biotechnology companies which the state
believed to be in the interest of the U.S. on the global arena).
76. WHITE HOUSE, supra note 69, at 4.
77. Meghani, supra note 73, at 735–37. See NAT’L ACAD. OF SCI., ENG’G,
AND MED., supra note 68, at 70 (evaluating the risk-based assessment based on
the characteristics of the organism, the target environment, and the type of
application).
78. WHITE HOUSE, supra note 69. See NAT’L ACAD. OF SCI., ENG’G, AND
MED., supra note 68, at 70 (providing a basic survey of statutory authorities of
the EPA, the FDA, and the USDA to regulate environmental and human health
and safety risks related to biotechnology products).
79. See Emily Waltz, A Face-lift for Biotech Rules Begin, 33 NATURE
BIOTECH., 1221 (2015) (explaining contexts for the 2017 update); Kelly Servick,
U.S. to Review Agricultural Biotech Regulations, 349 SCI. 131 (2015) (finding
the outdated framework has resulted in puzzling regulatory paths and a new
framework would help clarify each agency’s role and strategy); see Heidi
Ledford, Gene-editing Surges as US Rethinks Regulations, NATURE (Apr. 12,
2016),
https://www.nature.com/news/gene-editing-surges-as-us-rethinksregulations-1.19724 (considering that gene-edited products would fall outside
the scope of existing regulation).
80. WHITE HOUSE, supra note 69, at 1–2.
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based,81 the regulatory system should be grounded in risk
assessment,82 and existing statutory authorities of each agency
are sufficient to cover biotechnology products and their
applications.83 Importantly, the update ceased to identify lead
agencies which had caused confusion and been mistakenly
interpreted; instead it encouraged coordination and
communication among agencies and clarified “current
responsibilities and the relevant coordination across [the] EPA,
[the] FDA, and [the] USDA for the regulatory oversight of
[different] biotechnology products.”84 With such an upgrade in
the federal biotechnology regulatory system, the federal
government believed that it would “increase public confidence in
the regulatory system and prevent unnecessary barriers to
future innovation and competitiveness.”85
Despite the federal government’s attempt to clarify the roles
of each agency, the 2017 update still left each agency with
significant flexibility to determine whether it has regulatory
authority over certain genome-edited products under existing
statutes. Guided by the updated Coordinated Framework, the
agencies have made respective changes to their regulation of
genome-edited products.86 For example, the FDA has read the
existing statutes to cover genome-edited animals whereas the
USDA has proactively excluded certain genome-edited
organisms that are modified solely by genetic deletions from its
regulatory review.87 Even though the Coordinated Framework
confers considerable flexibility to the agencies, existing statutes

81. Id. at 8 (“Exercise of agency oversight within the scope afforded by
statutes should be commensurate with the risk posed by the introduction of the
biotechnology product and should not turn on the fact that it was created or has
been altered by a particular process or technique.”).
82. Id. at 7 (“It is the characteristics of the biotechnology product, the
environment into which it will be introduced, and the application of the product
that determine its risk (or lack thereof).”).
83. Id. (“Each agency uses its existing statutory authorities and regulations
to ensure the safety of the biotechnology products for their intended
applications. Underlying statutes define the boundaries of the scope of oversight
afforded to each regulatory agency.”).
84. Id. at 28.
85. WHITE HOUSE, supra note 69, at 1.
86. Emily Marden & Deepti A. Kulkami, Regulatory Pathways Emerged for
Gene-edited
Products,
LAW360
(Mar.
20,
2017),
https://www.law360.com/articles/903715/regulatory-pathways-emerge-forgene-edited-products.
87. Id.
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might not equip regulators with the best tools to regulate
emerging biotechnological products effectively since geneediting technologies were not contemplated by Congress when
these statutes were passed and amended.88
F. CURRENT REGULATORY PATHWAYS OF GENETICALLY
ENGINEERED ANIMALS WITH NON-CRISPR-LIKE TECHNOLOGIES
Within the Coordinated Framework, genetically engineered
animals using recombinant DNA or other similar technologies
are regulated under different agencies with different statutory
authorities according to their product area applications. Below
is an outline of various existing regulatory pathways of
genetically engineered animals.89
i. New Animal Drugs
In 2009, the FDA published a guidance regulating
genetically engineered animals under the new animal drugs
provisions under the FD & C Act by treating genetic material
that is integrated into the animal as a new animal drug.90 The
FDA followed the risk-based assessment laid out under the
Coordinated Framework, considering the introduced DNA’s
impact on animal health, effectiveness to the animal and, in the
case of food-producing animals, whether food derived from the
animal is safe for consumption.91 Under this guidance, the FDA
88. See NAT’L ACAD. OF SCI., ENG’G, AND MED., supra note 68, at 173
(acknowledging that “in some cases the jurisdiction of the agencies has the
potential to leave gaps in regulatory oversight.”).
89. This Note also recognizes that the FDA regulates therapeutic and
xenotransplantation products for human use derived from transgenic animals
through guidance. Genetically engineered animals are also covered by
applicable federal, state, local, and tribal laws pertaining to humane care,
environmental safety, import and export, etc. This Note, however, does not go
into detailed discussions of these regulations.
90. See 21 U.S.C. § 321(g)(1) (2018) (“The term ‘drug’ means: . . . (C) articles
(other than food) intended to affect the structure or any function of the body of
man or other animals.”). 21 U.S.C. § 321(v) (2018) (“The term ‘new animal drug’
means any drug intended for use for animals other than man . . . .”); Guidance
for Industry on Regulation of Genetically Engineered Animals Containing
Heritable Recombinant DNA Constructs, supra note 17 (maintaining that the
rDNA construct in a genetically engineered animal that is intended to affect the
structure or function of the body of the animal meets the FD & C Act’s drug
definition).
91. See Guidance for Industry on Regulation of Genetically Engineered
Animals Containing Heritable Recombinant DNA Constructs, supra note 17.
WHITE HOUSE, supra note 69, at 19 (listing the seven categories that the FDA
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has approved three animals,92 including the genetically
engineered salmon for human consumption.93
ii. New Drugs
Under the FD & C Act, the FDA also has regulatory
authority over new drugs that are developed through genetic
engineering,94 which include drugs produced from genetically
engineered animals.95 The FDA has developed regulations to
evaluate whether the drug is safe and effective and whether the
benefits outweigh the risks of the drug.96

applied in its review process: product definition, molecular characterization of
the construct, molecular characterization of the GE animal lineage, phenotypic
characterization of the GE animal, durability plan, environmental and food/feed
safety, and claim validation); the FDA should also conduct an environmental
assessment under the National Environmental Policy Act “with its approval of
genetically engineered animals under its animal drug licensing authority and
seek measures to ameliorate any anticipated adverse environmental effects.”
NAT’L ACADS., ANIMAL BIOTECHNOLOGY: SCIENCE-BASED CONCERNS 164
(2002).
92. See Sarah Polcz & Anna C.F. Lewis, A Menagerie of Moral Hazards:
Regulating Genetically Modified Animals, 46 J. L. MED. & ETHICS 180, 183
(2018) (including a goat that produces an anticlotting protein in its milk, a
chicken whose eggs contain a drug for a specific cholesterol disease, and salmon
that grows faster than normal).
93. See Ledford, supra note 60. Compare AquAdvantage Salmon Approval
Letter and Appendix, U.S. FOOD & DRUG ADMIN. (updated Dec. 1, 2017),
https://www.fda.gov/AnimalVeterinary/ucm466214.htm, and Freedom of
Information
Summary,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.fda.gov/downloads/animalveterinary/developmentapprovalprocess
/geneticengineering/geneticallyengineeredanimals/ucm466215.pdf, with S. 230,
112th Cong. (1st Sess. 2011) (proposing to amend the FD & C Act to prevent
approval of the genetically engineered salmon), and H.R. 521, 112th Cong. (1st
Sess. 2011) (preventing approval of the genetically engineered salmon).
94. See 21 U.S.C. § 321(p) (2018) (defining the term new drug as “any drug
(except a new animal drug or an animal feed bearing or containing a new animal
drug) the composition of which is such that such drug is not generally
recognized . . . as safe and effective for use . . . .”).
95. See, e.g., Justin Caba, FDA Finally Approves the First Drug to Treat
Rare Genetic Disease, Hereditary Angioedema, MED. DAILY (July 17, 2014),
https://www.medicaldaily.com/fda-finally-approves-first-drug-treat-raregenetic-disease-hereditary-angioedema-293656 (reporting that the FDA
approved a drug collected from the milk of lab-made rabbits to treat a genetic
disease that causes body swelling).
96. See generally 21 U.S.C. § 355 (2018).
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iii. Biologics
Under the Public Health Service Act, the FDA regulates
biological products that are produced from genetically
engineered animals.97 These biologics must be licensed by the
FDA which considers whether they are safe and effective for
their intended purpose.98
iv. Animal Pests
With the authority from the Animal Health Protection Act,
the USDA has developed a framework to regulate genetically
engineered animals by prohibiting or restricting imports or
entry and interstate movement of them if they are animals that
are considered livestock and that serve as animal pests
transmitting diseases.99 The regulatory framework does not
distinguish genetically engineered animals from non-genetically
engineered animals; the USDA, when deciding whether to issue
a permit for importing or transporting animal pests, considers
the animal health risk and the mitigations that can be applied
to reduce this risk.100
v. Others
The FDA and the USDA also share regulatory responsibility
to ensure food from genetically engineered animals for human
consumption is safe, wholesome, and correctly labeled.101
Besides the FDA’s attempt to cover genetically engineered
animals under the FD & C Act by categorizing inserted foreign
97. See 42 U.S.C. § 262(i)(1) (2017) (“The term ‘biological product’ means a
virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or
derivative, allergenic product, protein (except any chemically synthesized
polypeptide), or analogous product, or arsphenamine or derivative of
arsphenamine (or any other trivalent organic arsenic compound), applicable to
the prevention, treatment, or cure of a disease or condition of human beings.”).
98. See generally 42 U.S.C. §§ 262–263a-7 (1992).
99. See 7 U.S.C. § 8302(13) (2018) (“The term ‘pest’ means any of the
following that can directly or indirectly injure, cause damage to, or cause
disease in livestock: . . . (J) A vector. (K) Any organism similar to or allied with
any of the organisms described in this paragraph.”); Framework for the
Regulation of Genetically Engineered Animals and Insects Pursuant to the
Animal
Health
Protection
Act,
https://www.aphis.usda.gov/animal_health/downloads/framework-ee-ahpa.pdf.
100. See Framework for the Regulation of Genetically Engineered Animals
and Insects Pursuant to the Animal Health Protection Act, supra note 99.
101. See NAT’L ACADS., supra note 91, at 163 (including the FD & C Act, the
Federal Meat Inspection Act, and the Poultry Products Inspection Act).
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DNA sequences as a new animal drug,102 all the other
regulations by various agencies have not stirred up controversies
because they regulate genetically engineered animals in a way
that are not distinguishable from non-genetically engineered
animals.
G. THE FDA’S UPDATED GUIDANCE OVER GENOME-EDITED
ANIMALS WITH CRISPR-LIKE TECHNOLOGIES
In January 2017, as part of the federal efforts to update the
Coordinated Framework where the government was concerned
that new biotechnological products would slip off the existing
regulatory framework,103 the FDA published a draft updated
guidance #187 which interprets the new animal drug provisions
under the FD & C Act to cover products developed from CRISPRlike precision gene-editing technologies.104 As explained in
section F above, the previous guidance only addressed
transgenic animals, but not genome-edited animals created with
CRISPR-like technologies that result in “targeted DNA sequence
changes including nucleotide insertions, substitutions, or
deletions,” because the regulatory framework had not adapted
to the development of new technologies.105 Thus, this new draft
guidance is the FDA’s attempt to clarify that the altered genomic
DNA in an animal is “an article that meets the definition of a
new animal drug at each site in the genome where the alteration
(insertion, substitution or deletion) occurs” and therefore shall

102. See, e.g., GTC Biotherapeutics, Inc., Comment Letter on Food and Drug
Administration
Notice
(Nov.
15,
2018),
https://www.regulations.gov/document?D=FDA-2008-D-0394-0173
(arguing
that “the [] Guidance stretches a proper interpretation of the law”); John J.
Cohrssen & Henry I. Miller, Current FDA Approach to Genetically Engineered
Animals
Is
Flawed,
THE
HILL
(Nov.
6,
2017),
https://thehill.com/opinion/healthcare/358893-current-fda-approach-togenetically-engineered-animals-is-flawed (categorizing the rDNA technology as
one of the many animal breeding techniques and arguing that the animal drug
provisions impose high evidentiary standard on developers).
103. See Waltz, supra note 79 and accompanying texts.
104. See Regulation of Intentionally Altered Genomic DNA in Animals Draft
Guidance, supra note 18. See Nick Stockton, The FDA Wants to Regulate Edited
Animal
Genes
as
Drugs,
WIRED
(Jan.
24,
2017),
https://www.wired.com/2017/01/fda-wants-regulate-edited-animal-genesdrugs/.
105. Regulation of Intentionally Altered Genomic DNA in Animals Draft
Guidance, supra note 18.
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be covered by the FDA’s regulatory authority.106 Yet, this
guidance has faced an unanticipated outcry from researchers,
biotechnological companies, various environmental and industry
groups, as well as other federal agencies.107 Part II will discuss
the pitfalls of this guidance and propose alternative regulatory
pathways for genome-edited animals if the FDA does not have
the regulatory authority to do so.
II. ANALYSIS
Notably, current regulatory structures are not set up to
regulate CRISPR-like technologies.108 This Part recognizes the
FDA’s efforts to close the gaps under the current Coordinated
Framework to regulate genome-edited animals with CRISPRlike technologies through guidance #187 but argues that the
FDA has exceeded its vested statutory authority under the FD
& C Act which was passed in 1938. Furthermore, the FDA’s
approach signals a departure from the product-based and riskbased approach set in the Coordinated Framework. Rather, the
FDA focuses on the process from which genome-edited animals
are created. Moreover, instead of notice-and-comment
rulemaking, the FDA has chosen to issue a guidance document
that might not be adequate to address biotechnology products
and the impacts of their application on the environment and
human safety. Importantly, it is crucial to recognize that
regulating more than necessary and implementing a stringent
regulatory system will stifle innovation and shun scientists
away while leaving a genome-edited product completely outside
of regulatory oversight will be equally worrisome and stir up
public concerns. Therefore, a balance must be struck between
the competing concerns.

106. Id. Cf. George Washington University Regulatory Studies Center,
supra note 67 (noting that the guidance, however, excludes random
mutagenesis followed by phenotypic selection).
107. See, e.g., Williams, supra note 74, at 454 (contending that researchers
were hopeful that these gene-editing products would be regulated less
stringently than animals that are genetically engineered by introducing foreign
DNA).
108. See Greely, supra note 45 (noting that current statutes do not cover all
that CRISPR can accomplish); Brooke Borel, The U.S. Regulations for
Biotechnology Are Woefully Out of Date, SLATE (Apr. 21, 2017),
http://www.slate.com/articles/technology/future_tense/2017/04/u_s_biotechnolo
gy_regulations_are_woefully_out_of_date.html.
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A. THE FDA EXCEEDED ITS VESTED STATUTORY AUTHORITY TO
INTERPRET ALTERED GENOMIC DNAS AS NEW ANIMAL DRUGS.
Congress expressly delegated the authority of regulating
new animal drugs to the FDA under the FD & C Act which sets
the boundaries of the FDA’s scope of regulation.109 The FDA has
exceeded its vested authority by interpreting altered genomic
DNAs as new animal drugs.110 Under the FD & C Act, a new
animal drug is defined as “any drug intended for use for animals
other than man . . . . .”111 To qualify as a new animal drug, the
application must be a drug first which means an “article[]
intended to affect the structure or any function of the body of
man or other animals.”112 The FDA characterizes genome-edited
animals as equivalent to transgenic animals and thus treats
altered genomic DNA as the regulated article.113 However, many
industry groups or nonprofits disagree with the FDA’s
characterization and argue that the FDA’s attempt to assert
jurisdiction over the production and commercialization of
genome-edited animals is ultra vires because altered genomic
DNAs could not or would not be drugs.114
When the FDA issued the 2009 guidance to exercise
oversight of the recombinant DNA construct to an animal as new
animal drugs based on which it approved several transgenic
animals, it was already testing the limit of the scope of authority
vested by Congress under the FD&C Act. In the FDA’s most
recent guidance, however, it has moved past the tipping point
because under certain circumstances CRISPR-like technologies
do not involve insertion of foreign DNAs into the genome of a
targeted animal.
The FDA’s interpretation of a drug is erroneous. Under the
FD&C Act, a drug must be an article “intended to affect the
structure or any function of the body of man or other animals.”115

109. See generally 21 U.S.C. § 360b (2018).
110. See Guidance for Industry on Regulation of Genetically Engineered
Animals Containing Heritable Recombinant DNA Constructs, supra note 17.
111. 21 U.S.C. § 321(v) (2018).
112. 21 U.S.C. § 321(g)(1)(C) (2018).
113. See Guidance for Industry on Regulation of Genetically Engineered
Animals Containing Heritable Recombinant DNA Constructs, supra note 17.
114. See, e.g., Ctr. for Food Safety, supra note 21; cf. Consumers Union,
supra note 19.
115. 21 U.S.C. § 321(g)(1)(C) (2018); see also 21 U.S.C. § 321(g)(1), supra
note 90 and accompanying texts.
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Unquestionably, the altered genomic DNA affects the structure
or function of the animal to obtain desirable traits; for example,
the altered genomic DNA in the cattle transforms it into a
hornless one.116 Nevertheless, the altered genomic DNA is not
an article. The FD&C Act does not define article and the FDA
has pointed out that the term has a “broad meaning” throughout
the FD & C Act.117 The dictionary definition of “article” is “a
thing or person of a . . . distinctive kind or class.”118 Distinctive
means “separate or different.”119 Thus, an article must be
separate and different from the recipient animal and therefore
is “a necessary addition to induce a change to the structure or
function of man or animal.”120
Under certain circumstances, altered genomic DNAs using
CRISPR-like technologies are not separate articles that are
introduced into the recipient animal, but rather, products
resulted from the cutting of Cas9 enzyme in vivo.121 When using
CRISPR-Cas9 to delete genetic material from the target cell,
scientists introduce nothing new into the genome and the altered
genomic DNA does not contain any foreign article that modifies
the structure or function of the animal.122 The FDA must
distinguish this gene-editing process from a transgenesis
process where a recombinant DNA construct is created
externally outside an animal and then inserted into the animal’s
genome. With genome-edited animals, the targeted DNA
sequences are part of the animal’s genome, not a foreign
addition, and the gene-editing process occurs completely in vivo,
not ex vivo.123 Therefore, the altered genomic DNA does not fit
the definition of a drug under the FD & C Act because of the
absence of an article as “a necessary addition” to the animal.124

116. See supra Section I.B.
117. See 21 U.S.C. § 321 (2018); see also Pharmanex v. Shalala, 221 F.3d
1151, 1155 (10th Cir. 2000).
118. Article, MERRIAM-WEBSTER DICTIONARY (2019).
119. Distinctive, MERRIAM-WEBSTER DICTIONARY (2019).
120. Nat’l Milk Producers Fed’n, Comment Letter on The Food and Drug
Administration’s Draft Guidance for Industry #187 “Regulation of Intentionally
Altered
Genomic
DNA
in
Animals”
(June
19,
2017),
https://www.regulations.gov/document?D=FDA-2008-D-0394-0413.
121. See supra section I.A.
122. See Nat’lMilk Producers Fed’n, supra note 121.
123. See id.
124. The conclusion of this section has limited implication on gene therapy
using CRISPR-like technologies. Currently, the FDA regulates gene and cell
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B. THE FDA’S GUIDANCE DEVIATES FROM THE CONVENTIONAL
PRODUCT-BASED REGULATORY SCHEME SET FORTH IN THE
COORDINATED FRAMEWORK.
Other than the legal flaws identified above, the FDA’s
guidance has not followed the policy set forth under the
Coordinated Framework. The guidance deviates from the
traditional product-based approach and focuses on the process
that the animals are created by using CRISPR-like technologies
instead.125 It assumes that all gene-editing techniques are
dangerous and “deemed unsafe” by construing altered genomic
DNAs as new animal drugs.126
New gene-editing technologies like CRISPR-Cas9 underpin
the inherent flaws of a process-based approach. First, animals
created from gene-editing technologies impose less risk than
those created from recombinant DNA technologies.127 Currently,
there is no scientifically objective method to distinguish animals
created from conventional breeding methods from animals
developed through use of gene-editing methods,128 and
sometimes conventionally bred animals pose more risk than

therapy products under, among others, the Investigational New Drug
Application. 21 C.F.R. § 312. When a cell is modified ex vivo for subsequent
administration to humans, the cell can be construed as a drug under the FD &
C Act. However, when the cell is altered in vivo using CRISPR-like technologies,
no foreign article is inserted into the cell which cannot be construed as a drug
itself. Regardless, the FDA has created expedited programs for regenerative
medicine therapies that include human gene therapies, regardless how a cell is
modified. See generally Expedited Programs for Regenerative Medicine
Therapies for Serious Conditions: Draft Guidance for Industry, 82 FED. REG.
4825 (Feb. 19, 2019).
125. See supra note 73 and accompanying texts. Cf. James D. Murray &
Elizabeth A. Maga, Regulatory Dysfunction Inhibits the Development and
Application of Transgenic Livestock for Use in Agriculture, in ANIMAL
BIOTECHNOLOGY 2: REPRODUCTIVE BIOTECHNOLOGIES 149, 157 (Heiner
Niemann & Christine Wrenzycki eds., 2018) (finding that to date, worldwide
governments have for the most part chosen to regulate the process of making a
genetically engineered animal instead of the resulting product).
126. Regulation of Intentionally Altered Genomic DNA in Animals Draft
Guidance, supra note 18.
127. See Section I.B.
128. The George Washington University Regulatory Studies Center, supra
note 67, at 6; Jonas J. Monast, Editing Nature: Reconceptualizing Biotechnology
Governance, 59 B. C. L. REV. 2377, 2399 (2018) (arguing that if CRISPR is
analogous to selective breeding or natural selection, it follows that genomeedited organisms are no less natural than their counterparts that could foster
similar genetic changes through conventional reproduction).
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genome-edited animals.129 Thus, under a process-based
approach, genome-edited animals are subject to a similar or
higher level of regulation than transgenic and conventionally
bred animals even though genome-edited animals entail less
risk of unintended changes to the genome.130 An assumption of
risk based solely on the use of a certain technique runs against
the Coordinated Framework and can warrant regulatory
oversight by the FDA.
Second, a process-based approach would stunt scientific
development in gene-editing or other biotechnologies.131 If premarket oversight is imposed on all genome-edited animals using
CRISPR-like techniques, only big corporations would be able to
afford expensive and time-consuming health and environmental
assessments while small companies would be unable to finance
these costly safety assessments.132 One might argue that only
big corporations should be allowed to carry out biotechnology

129. See George Washington University Regulatory Studies Center, supra
note 67, at 6 (finding that random mutagenesis followed by phenotypic selection
would result in more genome alterations).
130. See Alison Peck, Re-Framing Biotechnology Regulation, 72 FOOD &
DRUG L. J. 314, 331–33 (2017) (finding that under a process-based approach,
conventional breeding technologies would also fall under the scope of
regulation); Pak, supra note 23 (discussing whether CRISPR-Cas9 is genetic
engineering or a form of mutagenesis which is not subject to U.S. regulation);
Kathleen M. Vogel, Crispr Goes Global: A Snapshot of Rules, Policies, and
Attitudes, THE BULLETIN (June 5, 2018), https://thebulletin.org/2018/06/crisprgoes-global-a-snapshot-of-rules-policies-and-attitudes/ (finding that the EU
court exempted crops created by gene-editing technologies from regulations
because the result is nature-identical); see also Gregory Conko et al., A Riskbased Approach to the Regulation of Genetically Engineered Organisms, 34
NATURE BIOTECHNOLOGY 493 (2016) (finding that most regulatory regimes
around the world do not follow the risk-based approach and that the degree of
regulatory scrutiny in most cases is inversely proportional to the risk).
131. See Tomlinson, supra note 8, at 461 (quoting that the irony of subjecting
groundbreaking scientific discoveries to an archaic regulatory scheme is
causing many researchers to lose faith in the system); Marden & Kulkami,
supra note 86 (exploring the impracticability of proposed regulatory changes
that slow down development).
132. Rubin & Sax, supra note 72, at 596–97 (“Depending on how many
agencies a firm may need to petition or voluntarily consult, the process
currently requires ten years to bring a new GM product to market.”); Jack
Karsten & Darrell M. West, New Biotech Regulations Require Balance of Safety
and
Innovation,
BROOKINGS
(Mar.
3,
2017),
https://www.brookings.edu/blog/techtank/2017/03/03/new-biotech-regulationsrequire-balance-of-safety-and-innovation/ (discussing concern for proposed
regulations that could limit competition and innovation).
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research because of their efficiency, economies of scale, and high
standards of quality, but these advantages of big corporations
seem ironic when CRISPR-like technologies democratize
scientific applications and make gene-editing more accessible
and economical.133 The stringent process-based approach will
likely push innovations to jurisdictions that provide a regulatory
environment more hospitable to entrepreneurial activities and
cause the U.S. to lose its competitive advantage in biotechnology
fields.134
Third, a process-based regulatory approach would almost
inevitably fall behind time and future development of
biotechnology products.135 Soon, there will be new technologies
beyond CRISPR-Cas9 such as genomically recoded organisms
created via synthetic DNA.136 Agencies simply do not have the
resources to develop new regulations in reaction to every new
technology,137 and a constantly changing regulatory landscape
creates regulatory uncertainties that might stifle innovation.138
In contrast, a product-based approach “specifies required
outcomes or objectives rather than defining the way in which

133. See supra section I.B.
134. Thierer, supra note 22 (“If policymakers erect more obstacles to
innovation, it will encourage entrepreneurs to look elsewhere when considering
the most hospitable place to undertake their innovative activities.”); see Kevin
Bryant, Ph.D., Top 9 CRISPR Startup Companies Changing the Future of
Biotech and Medicine, SYNTHEGO, https://www.synthego.com/blog/crisprstartup-companies (last updated Jan. 3, 2019) (providing a list of startups
applying CRISPR to various fields).
135. See NAT’L ACAD. OF SCI., ENG’G, AND MED., supra note 68, at 174 (“The
profusion of future biotechnology products anticipated in coming years will
challenge the federal agencies’ ability to handle significant increases in the rate
of biotechnology product innovation, the number of biotechnology products, the
complexity of interactions, and the diversity of actors (and their experience with
the regulatory process).”).
136. Id. at 172.
137. For example, the FDA had to create new guidance documents from 2009
to 2017 in reaction to the emerging technologies like CRISPR-Cas9. William D.
Eggers, Mike Turley & Pankaj Kishnani, The Future of Regulation: Principles
for Regulating Emerging Technologies, DELOITTE INSIGHTS (June 19, 2018),
https://www2.deloitte.com/insights/us/en/industry/public-sector/future-ofregulation/regulating-emerging-technology.html (“The policy cycle often takes
anything from five to 20 years whereas a unicorn startup can develop into a
company with global reach in a matter of months.”).
138. See also Ann Bruce, Novel GM Animal Technologies and Their
Governance, 22 TRANSGENIC RES. 681, 688 (2013) (arguing that regulatory
uncertainty would also make it difficult for developers to assess the relative
commercial advantage of the new technology and limit market innovation).
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they must be achieved.”139 This approach is better at adapting to
scaling modern innovations because the outcomes set by the
regulators are unaffected by the development of new
technologies.
Thus, when carrying out a benefit-risk assessment,140 the
FDA should have considered the risks of the product, the
genome-edited animal, not the risks of the process, CRISPRCas9. It should have considered the effects of modified genetic
material on the animal and whether food derived from the
animal is safe for human consumption.141 For the forgoing
reasons, the FDA should ground its regulatory approach in the
product-based approach identified in the Coordinated
Framework.
C. WHEN FACING A SIMILAR SITUATION, THE USDA ADHERED TO
THE PRODUCT-BASED APPROACH AND EXCLUDED GENOMEEDITED CROPS WITH CRISPR-LIKE TECHNOLOGIES FROM ITS
JURISDICTION.
This Note recognizes that existing statutes and the current
framework were not conceived to cover biotechnologies like
CRISPR-Cas9. Nevertheless, it is not impossible to work with
existing statutes while conforming to the Coordinated
Framework. In 2016, the USDA had to determine whether it has
the jurisdiction to regulate a type of CRISPR-edited antibrowning mushroom.142 Under the USDA’s regulation, a
genetically engineered organism is deemed a regulated article “if
it has been genetically engineered using a donor
organism . . . that . . . meets the definition of a plant
pest . . . .”143 Unlike the FDA, the USDA determined that the
genome-edited mushroom was beyond its regulatory authority
because
the
“CRISPR/Cas9-edited
white
button
139. Eggers, Turley & Kishnani, supra note 138.
140. See 21 U.S.C. § 355(d) (2018) (requiring a risk-benefit assessment
framework).
141. See Nat’l Assn. of State Dep’t of Agric., supra note 21 (arguing for these
considerations).
142. See U.S. Dep’t of Agric., Re: Request for Confirmation that Transgenefree, CRISPR-edited Mushroom Is Not a Regulated Article (Apr. 13, 2016)
[hereinafter
USDA
Confirmation
Request]
https://www.aphis.usda.gov/biotechnology/downloads/reg_loi/15-32101_air_response_signed.pdf (assessing the potential regulation of the
mushroom in question).
143. 7 C.F.R. § 340.1 (2019).
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mushrooms . . . do not contain any introduced genetic
material,”144 and therefore, is not a regulated article.
Additionally, the USDA announced that it would not
regulate crops that “could otherwise have been developed
through traditional breeding techniques as long as they are not
plant pests or developed using plant pests.”145 Genome-edited
plants with CRISPR-like technologies could also be obtained
through traditional breeding techniques as they do not contain
artificially inserted genes from other species.146 Therefore, they
will not be overseen by the USDA. Compared to the FDA’s
approach, the USDA’s approach towards genome-edited plants
is much more nuanced, distinguishing genome-edited plants
from genetically engineered plants by recombinant DNA
techniques and adhering to the product-based approach outlined
under the Coordinated Framework. The FDA could have
adopted a similar approach towards genome-edited animals to
encourage more beneficial innovations.
D. THE FDA SHOULD HAVE PROMULGATED RULES VIA NOTICEAND-COMMENT PROCEDURE.
Lastly, the FDA could have promulgated a rule via the
notice-and-comment process that would determine the
circumstances under which genome-edited animals could be
brought into the market, but it chose to issue a non-binding
guidance document instead. The FDA defines guidance
documents in its Good Guidance Practices (GGPs) as documents
that “describe the agency’s interpretation of or policy on a
regulatory issue” and establish no “legally enforceable rights or
responsibilities.”147 Yet, when the FDA interprets the new
animal drug provisions under the FD&C Act to cover altered
genomic DNAs, instead of making an interpretive rule, it is
144. USDA Confirmation Request, supra note 143; see also Irus Braverman,
Editing the Environment: Emerging Issues in Genetics and the Law, in GENE
EDITING, LAW, AND THE ENVIRONMENT: LIFE BEYOND THE HUMAN 1, 7 (Irus
Braverman ed., 2018) (discussing the USDA’s decision regarding the
mushroom).
145. Press Release, U.S. Dep’t of Agric., Secretary Perdue Issues USDA
Statement
on
Plant
Breeding
Innovation
(Mar.
28,
2018),
https://www.usda.gov/media/press-releases/2018/03/28/secretary-perdueissues-usda-statement-plant-breeding-innovation (“With this approach, USDA
seeks to allow innovation when there is no risk present.”).
146. See supra section I.B.
147. 21 C.F.R. § 10.115 (2018).
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actually making a legislative rule which imposes “a definitive
obligation on a group of private persons.”148 Though the GGPs
pronounces that a guidance document is not binding and affected
parties may choose alternative approaches other than the one
set forth in a guidance document,149 the regulated parties would
not “feel comfortable using anything other than the suggested
form.”150
Moreover, guidance documents afford little procedural
safeguard to the public. The notice-and-comment process
provides interested individuals with a meaningful opportunity
to comment on the proposed rule through the submission of
written “data, views, or arguments,”151 of which significant
comments must be incorporated into the final rule.152 Affected
individuals may challenge the rulemaking process on an
arbitrary and capricious standard if the agency fails to consider
public comments.153 Guidance documents, however, are exempt
from this requirement. Section 553 of the Administrative
Procedure Act (APA) provides that “interpretative rules, general
statements of policy, or rules of agency organization” are
excluded from the notice-and-comment requirements, and
administrative guidance falls under the exception of
interpretative rules.154 Instead of addressing all significant
comments in the final rule, the FDA only needs to incorporate
comments if it deems appropriate.155 By resorting to issuing an
administrative guidance, the FDA attempted to circumvent the
increasing scrutiny the courts have devoted to notice-andcomment rulemaking.156
148. Rubin & Sax, supra note 72, at 571.
149. See 21 C.F.R. § 10.115 (2018).
150. See Rubin & Sax, supra note 72, at 571–72 (“In legal doctrine or a lawschool classroom, there may be a great difference between disobeying and
annoying a government agency, but in the real, regulated world, that difference
is not as evident.”).
151. 5 U.S.C. § 553(c) (2018).
152. See Perez v. Mortg. Bankers Ass’n, 135 S. Ct. 1199, 1203 (2015) (“An
agency must consider and respond to significant comments received during the
period for public comment.”).
153. See 5 U.S.C. § 706(2)(A) (2018) (invoking the arbitrary and capricious
standard).
154. 5 U.S.C. § 553(b)(3)(A) (2018).
155. See 21 C.F.R. § 10.115 (2018).
156. Rubin & Sax, supra note 72, at 540–42, 566 (criticizing guidance as an
improper attempt of rulemaking and one of the most controversial techniques
in administrative law).
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Notably, one might argue that by issuing a guidance
document which is a soft law mechanism, agencies can now
adapt quickly to changes in technology and address issues as
they arise without stifling innovation.157 However, when
regulated products might potentially pose unknown risks to the
environment and human health, the regulation should, at least,
provide a basis for a legal challenge and thus allow for judicial
review.158 The public needs an avenue to understand genomeedited products and thereby “reduc[e] irrational fears about
[their] safety,” and small firms need an avenue to promote the
benefits they could offer to the public and the market, “or at least
compel the [a]gency to defend the burdens it imposes on these
firms.”159 Thus, a guidance document which does not confer the
public with a sufficient participatory mechanism is not the best
tool to deal with genome-edited products and the FDA should
have issued a rule through the informal rulemaking process
under the APA.
The FDA’s guidance #187 faces so many legal, procedural,
and policy challenges that the agency must come up with a new
regulatory approach towards genome-edited animals with
CRISPR-like techniques. If the FDA were to find that it lacks
any authority to extend its jurisdiction over genome-edited
animals, other agencies might be able to fill in this gap.
III. POLICY CONSIDERATIONS MOVING FORWARD
The analysis above has identified a few gaps within the
current regulatory structures, which were not created to
regulate genome-edited animals with emerging biotechnologies.
Therefore, with these pitfalls of the FDA’s draft guidance, this
Part proposes several alternative pathways to regulate genomeedited animals with CRISPR-like technologies. Additionally,
under the current Coordinated Framework, agencies follow a
product- and risk-based approach to regulate genome-edited

157. See William McGeveran, Friending the Privacy Regulators, 58 ARIZ. L.
R. 959, 987 (2016) (explaining how flexible regulation can help regulators
remain responsive to rapid technological change).
158. Cf. Rubin & Sax, supra note 72, at 587 (highlighting the weakness in
the Coordinated Framework used to regulate genetically modified food because,
as an administrative guidance, and thus a planning document, it provided no
basis for a legal challenge or judicial review).
159. Id. at 599.
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animals.160 However, a traditional risk-based approach faces
limitations in the context of new biotechnologies such as
CRISPR-Cas9 when the risks associated are uncertain and
ambiguous. Thus, there is an urgent need for the White House
to creates a framework with a single point of entry to regulate
genome-edited products, and update the Coordinate Framework
to incorporate the Responsible Research and Innovation (RRI)
principles to balance precaution and innovation, process and
product, as well as interests of developers and the public.
A. REGULATORY GAP AND ALTERNATIVE REGULATORY
PATHWAYS FOR GENOME-EDITED ANIMALS WITH CRISPR-LIKE
TECHNOLOGIES UNDER EXISTING STATUTES
Although the FDA’s updated guidance has many
controversial aspects of regulating genome-edited animals, it
indicates the agency’s attempt to fill in the gap of agency
jurisdiction under the Coordinated Framework. Were the FDA
to find that it lacks the jurisdiction to cover genome-edited
animals under existing statutes, letting them fall completely
outside of oversight, like how the anti-browning mushroom fell
outside of the USDA’s jurisdiction, it might not be an assuring
idea for the public at large.161
The FDA no longer has to be the lead agency exercising
oversight of animals for human use after the 2017 update to the
Coordinate Framework which encouraged agencies to coordinate
amongst each other.162 Therefore, federal agencies might explore
alternative pathways to exercise oversight of genome-edited
animals with CRISPR-like technologies.163 One possible solution

160. See WHITE HOUSE, supra note 69, at 8 (“Exercise of agency oversight
within the scope afforded by statutes should be commensurate with the risk
posed by the introduction of the biotechnology product and should not turn on
the fact that it was created or has been altered by a particular process or
technique.”).
161. See Mark Shwartz, Target, Delete, Repair, STAN. MED.,
https://stanmed.stanford.edu/2018winter/CRISPR-for-gene-editing-isrevolutionary-but-it-comes-with-risks.html (last visited Mar. 26, 2019) (“When
it comes to experiments on animals, . . . two things worry me . . . . One is the
intentional misuse of CRISPR. The other is that people with good intentions
will inadvertently cause harm.”) (citing Stanford bioethicist Hank Greely, JD).
162. See WHITE HOUSE, supra note 69, at 29.
163. The FDA could still exercise oversight of genome-edited animals if they
are used to create new human drugs and biological products; the USDA could
continue regulating genome-edited animals as animal pests that transmit
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for the agencies, a solution that has not been explored at all, is
to regulate the construct inserted into the targeted animal—the
guide RNA and the Cas9 protein—instead of the altered genomic
DNA.
i.

New Animal Drug under the FD&C Act

Although the altered genomic DNA is not a drug, the FDA
might, one day, regulate the guide-RNA/Cas9 construct inserted
into the targeted animal as a new animal drug.164 The key
question to determine is whether this construct constitutes a
drug or medical device. Under the FD&C Act, a medical device
is an article that is “intended to affect the structure or any
function of the body of man or other animals” and “does not
achieve its primary intended purposes through chemical
action.”165 When the construct is inserted into the targeted cell,
Cas9 binds specifically to the targeted DNA and cleaves the two
DNA strands to get rid of particular genetic material.166 It is
generally acknowledged among scientists that when Cas9
cleaves the DNA strands, it is catalyzing the splitting of the
chemical bonds in the strands.167 If the DNA cleavage is
characterized as a chemical action, then the construct will likely
be a new animal drug; otherwise, the construct will likely be a
medical device.
The interpretation of the term “chemical action” is a
nuanced one that the FDA and the scientific community
constantly grapple with.168 The FDA clarified in the guidance
that “a product that exhibits . . . intermolecular forces does not
diseases. For regulatory purposes, genome-edited animals are not
distinguishable from other animals. See supra section I.F.
164. The FDA is charged with protecting the public health by ensuring that
animal drugs are safe and effective. 21 U.S.C. § 393(b)(2)(B) (2018).
165. 21 U.S.C. § 321(h)(3) (2018).
166. See GALLO ET AL., supra note 10, at 2–3 (explaining how the CRISPRCas9 system functions).
167. See, e.g., Cong Huai et al., Structural Insights into DNA Cleavage
Activation of CRISPR-Cas9 System, NATURE COMM. 2 (Nov. 9, 2017),
https://www.nature.com/articles/s41467-017-01496-2 (“[T]hen, the two nuclease
domains (HNH and RuvC) catalyze the splitting of the scissile [covalent
chemical] bonds in two DNA strands, respectively.”).
168. See Classification of Products as Drugs and Devices and Additional
Product Classification Issues, 82 FED. REG. 44802, 44803 (Sept. 26, 2017)
(explaining how following public comments the FDA revised the guidance to
more clearly explain the agency’s thinking regarding the interpretation of
“chemical action.”).
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exhibit ‘chemical action’ under section 210(h) unless the
product . . . mediates a bodily response at the cellular or
molecular level . . . .”169 The guidance also illustrates that a
catalyst interacts with the body through intermolecular forces
and “mediates a bodily response at the cellular or molecular level
by catalyzing a number of enzymatic reactions of the
body . . . .”170 Similar to the catalyst example, when Cas9 binds
to the targeted DNA and cleaves the strands, it interacts with
the strands through intermolecular forces and triggers the cell
to repair the damage by such cleavage.171 Therefore, it is likely
that the DNA cleavage exhibits chemical action and thus, the
guide-RNA/Cas9 construct is not a medical device, but a drug
under the FD & C Act.
ii. Veterinary Biologic under the Virus-Serum-Toxin Act
(VSTA)
Alternatively, the USDA might be able to construe the
guide-RNA/Cas9 construct as a veterinary biologic and thus
regulate it under the VSTA.172 Veterinary biologics are “products
derived from living organisms and biological processes” that are
“used to prevent, diagnose, or treat animal diseases.”173 The
USDA must approve a veterinary biologic to be “pure, safe,
potent, and efficacious” before it is introduced into the market.174
Currently, scientists have succeeded in disrupting the prion
gene that can cause the mad cow disease with CRISPR-Cas9 to

169. FOOD & DRUG ADMIN., GUIDANCE FOR THE INDUSTRY AND FDA STAFF:
INTERPRETATION OF THE TERM ‘CHEMICAL ACTION’ IN THE DEFINITION OF
DEVICE UNDER SECTION 201(H) OF THE FEDERAL FOOD, DRUG, AND COSMETIC
ACT
3
(2017),
available
at
https://www.pharmamedtechbi.com/~/media/Supporting%20Documents/The%
20Gray%20Sheet/38/40/chemical_action_guidance.pdf (distributing a draft
guidance for comment purposes only).
170. Id.
171. See Univ. of Cal. Berkeley, supra note 39.
172. See generally 21 U.S.C. §§ 151–159 (2018) (conferring authority for the
Secretary of Agriculture to regulate “any virus, serum, toxin, or analogous
product for use in the treatment of domestic animals.”).
173. U.S. DEP’T AGRIC., PROGRAM AID NO. 1713, VETERINARY BIOLOGICS:
USE AND REGULATION 1 (2013). The statute does not define the term “veterinary
biologic.” See 21 C.F.R. § 510.3 (listing definitions).
174. Common Questions About Veterinary Biologics, U.S. DEP’T OF AGRIC.,
https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/veterinarybiologics/ct_vb_pel_faqs (last modified July 17, 2015).
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prevent cattle from contracting the disease.175 In this case, the
guide-RNA/Cas9 construct can be construed as a veterinary
biologic that prevents animal diseases in cattle by knocking out
the responsible gene, since the USDA already licensed the first
veterinary RNA vaccine in 2012.176 As such, the USDA might be
able to regulate the guide-RNA/Cas9 construct as a veterinary
biologic.
iii. Pesticide Under the Federal Insecticide, Fungicide, and
Rodenticide Act (FIFRA)
Lastly, the EPA might be able to construe the guideRNA/Cas9 construct as a pesticide and thus regulate it under
the FIFRA.177 Pesticide means any substance “intended for
preventing, destroying, repelling, or mitigating any pest.”178 In
the United States, genetically engineered insects have already
been released into the environment—Oxitec mosquitoes that
combat Zika—and have been regulated as a pesticide by the EPA
because they are intended to reduce the population of
mosquitoes in future generations and bring the species to its
extinction.179 Recently, scientists have succeeded in using
CRISPR-Cas9 to wipe out a type of mosquito “in as few as seven

175. See THE NETH. COMM’N ON GENETIC MODIFICATION, CRISPR &
ANIMALS: IMPLICATIONS OF GENOME EDITING FOR POLICY AND SOCIETY 34
(2018); see also Helen Briggs, ‘Tuberculosis-resistant’ Cattle Developed in China,
BBC (Feb. 1, 2017), https://www.bbc.com/news/science-environment-38810073
(reporting tuberculosis-resistant cattle has been created using the CRISPRCas9 system).
176. U.S. DEP’T OF AGRIC., supra note 173, at 9; see also New Swine Flu
Vaccine
Licensed,
NAT’L
HOG
FARMER
(Oct.
8,
2012),
https://www.nationalhogfarmer.com/health/new-swine-flu-vaccine-licensed
(reporting that the USDA approved a swine influenza virus H3N2 vaccine that
utilizes RNA Particle Technology).
177. The EPA is charged with protecting human health and the environment
by ensuring registered pesticide products result in no unreasonable adverse
effects to man or the environment. 7 U.S.C. § 136a(c)(5) (2018).
178. 7 U.S.C.§ 136(u) (2018).
179. See U.S. FOOD & DRUG ADMIN., CLARIFICATION OF FDA AND EPA
JURISDICTION OVER MOSQUITO-RELATED PRODUCTS: GUIDANCE FOR INDUSTRY
6 (2017) (clarifying the regulatory role the EPA shares in gene edited
mosquitos); Andrew Hammond, Here’s the Plan to End Malaria with CRISPRedited Mosquitoes, WIRED (Sept. 24, 2018), https://www.wired.com/story/heresthe-plan-to-end-malaria-with-crispr-edited-mosquitoes/
(explaining
how
genetically modified sterile mosquitos were released into the wild to combat
Zika in America).
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generations.”180 In this case, the guide-RNA/Cas9 construct
inserted into the mosquito genome, together with the resulted
mosquito, functions as a pesticide that annihilates the mosquito
population, making it subject to the EPA’s jurisdiction.181 Future
pesticide-like genome-edited animals might also be subject to
this regulatory pathway instead of being regulated by the FDA.
Although these agencies might be vested with the statutory
authority to exercise oversight of the guide-RNA/Cas9 construct,
it might not be a sound policy for them to do so because
regulating the construct in this way would focus purely on the
process, running counter to the product-based approached laid
out under the Coordinated Framework.182 Additionally, with the
constant change in technologies, regulations cannot be grounded
in a particular process but must stay flexible to remain relevant
and effective.183 As such, the White House must set up a new
framework to facilitate the agencies to determine the fine
balance between encouraging innovation and rendering
oversight of new technologies.
B. THE WHITE HOUSE SHALL UPDATE THE COORDINATED
FRAMEWORK WITH THE RRI PRINCIPLES THAT BALANCES
PRECAUTION AND INNOVATION POTENTIAL OF GENOME-EDITED
PRODUCTS
i. Limitations of a Risk-Based Approach towards GenomeEdited Products
The Coordinated Framework has adopted a risk-based
approach towards biotechnological products.184 As explained in
the section above, a risk-based approach assesses risks based on
characteristics of the organism, the target environment, and the

180. Hammond, supra note 179.
181. See U.S. FOOD & DRUG ADMIN., supra note 179.
182. See discussions supra section II.A.ii.
183. See NAT’L ACAD. OF SCI., ENG’G, AND MED., supra note 68, at 93–99
(“[A]lthough the products of future biotechnology are often likely to be within
the jurisdiction of existing regulators, they may struggle to regulate these
products effectively and to respond nimbly to the products that will be coming.”);
Meagan Davis, The Proper Regulation and the Use of CRISPR/Cas9 in the 21st
Century 14 (Apr. 2018) (unpublished student essay) (on file with the College of
Saint Benedict/Saint John’s University) (“With the constant change of
technology, regulations need flexibility and stability to stay relevant and
effective”).
184. See Meghani, supra note 73 and accompanying texts.
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type of application.185 Currently, the quantitative risk
assessment is widely used for new biotechnological products,
which means that the risk of the new organism on the ecologic
environment and human health is quantified by measurable,
objective data.186
However, a risk-based assessment works best only when the
risks are “clearly defined and quantifiable.”187 Risks of genomeedited animals with emerging biotechnologies like CRISPRCas9 are uncertain, ambiguous, and unfamiliar because of their
“inherent fluid boundaries, possible fields of application, and the
unknown and extremely dynamic future developments.”188
Currently, there is no sufficient baseline of information to
accurately assess the risks of products created with new
technologies.189 Thus, a risk-based approach is handicapped
when the risks of genome-edited products cannot be quantified
and evaluated against their benefits.
ii. Moving toward RRI to Address Risks While Fostering
Public-Welfare-Oriented Responsible Innovation
Given the unique nature of CRISPR-like technologies and
the likelihood of having future biotechnologies that no one could
have foreseen, U.S. agencies should move towards an approach
that finds the right balance between precaution and
innovation.190 On the one hand, regulators should be wary of the
unknown risks associated with genome-edited products on the
environment, human health, and safety. On the other hand,
regulatory agencies cannot inhibit innovation.191 Future
regulation will need to balance the dynamic relationships of “the
nature of the innovative products developed, their areas of

185. See WHITE HOUSE, supra note 69 and accompanying texts.
186. NAT’L ACAD. OF SCI., ENG’G, AND MED., supra note 68, at 150.
187. See Matthias Braun & Peter Dabrock, Mind the Gaps!, EMBO REPORTS
(Dec.
27,
2017),
http://embor.embopress.org/content/early/2017/12/27/embr.201745542.
188. Id.
189. NAT’L ACAD. OF SCI., ENG’G, AND MED., supra note 68, at 152.
190. Nina Duensing et al., Novel Features and Considerations for ERA and
Regulation of Crops Produced by Genome Editing, FRONTIERS IN
BIOENGINEERING
&
BIOTECHNOLOGY
,
June
2018,
at
14,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016284/pdf/fbioe-0600079.pdf.
191. See Braun & Dabrock, supra note 197.
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application, and the time-scales for their development.”192 When
in doubt, responsible governance demands the agencies “give
precedence to the protection of human dignity, human health or
the environment, rather than to organizational or economic
interests.”193
With these principles in mind, the White House could
update the Coordinated Framework with the RRI principles and
move towards a participatory approach that allows the agencies
to work with all societal actors during the innovation process
and to bring out new technologies that are reconciled with
societal values, needs, and expectations.194 Philosopher and
Scientist René von Schomberg notes that:
Responsible Research and Innovation is a transparent,
interactive process by which societal actors and innovators
become mutually responsive to each other with a view to the
(ethical) acceptability, sustainability and societal desirability of
the innovation process and its marketable products (in order to
allow a proper embedding of scientific and technological
advances in our society).195
A risk-based approach often values expert knowledge and
authority. With public participation, regulators have better
knowledge of what laypeople consider important and what
innovations might be acceptable and socially desirable.196
Rather than hindering a potentially risky product from being
marketed, RRI promotes the continuous involvement of various
stakeholders and considers various perspectives so that a

192. Bruce, supra note 139, at 690. See also Williams, supra note 74, at 458
(arguing that regulatory review must “balance the interest of the public, the
affected organism, and the environment.”).
193. Braun & Dabrock, supra note 197.
194. See EURO. COMM’N., Responsible Research & Innovation (last visited
Mar.
8,
2019),
https://ec.europa.eu/programmes/horizon2020/en/h2020section/responsible-research-innovation (“RRI implies that societal actors
(researchers, citizens, policy makers, business, third sector organizations, etc.)
work together during the whole research and innovation process in order to
better align both the process and its outcomes with the values, needs and
expectations of society.”).
195. René von Schomberg, A Vision of Responsible Research and Innovation,
in RESPONSIBLE INNOVATION: MANAGING THE RESPONSIBLE EMERGENCE OF
SCIENCE AND INNOVATION IN SOCIETY 51, 63 (Richard Owen et al. ed., 2013).
196. See Alexander Bogner & Helge Torgersen, Precaution, Responsible
Innovation and Beyond – In Search of a Sustainable Agricultural Biotechnology
Policy,
FRONTIERS
IN
PLANT
SCI.
(Dec.
18,
2018),
https://www.frontiersin.org/articles/10.3389/fpls.2018.01884/full#note3.
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product can be better aligned with societal expectations.197
Under this framework, regulators are able to address the risks
of new products in the context of the acceptability of their
applications and to promote public welfare-oriented responsible
innovation.
iii. Adopting RRI to Regulate Genome-Edited Animals Using
CRISPR-Like Technologies
Applying the approach that balances precaution and
innovation to regulate genome-edited animals, the FDA and
other agencies could evaluate the risks of the use of CRISPRCas9 or other similar technologies in their applications, gather
inputs from the public regarding their acceptability of the
product applications, and work collaboratively with developers
to develop rules that will be aligned with public values and
expectations. For instance, the FDA might attach conditions to
approval of new genome-edited animals into the market to
ensure that the environmental and social benefits outweigh
harms.198 The FDA could even provide more carrots to
incentivize innovation that would improve animal welfare,
environmental, and social benefit—like the hornless breed of
cattle produced by Recombinetics.199
Remarkably, on October 30, 2018, the FDA announced a
new program, the Veterinary Innovation Program (VIP),
incentivizing animal biotechnological advancement while
ensuring the safety of animal products.200 Developers of certain
intentionally altered animals using genome-edited technologies
that “provide a benefit to human health, animal health, animal
well-being, or enhanced food production” may participate in the

197. Id.
198. For instance, in Denmark genetic modification of animals is “restricted
to applications benefitting human health and the environment.” See Bruce,
supra note 47, at 391. In the Netherlands, “genetic modification of animals for
food purposes needs a license requiring the product to serve a public interest
and have no overriding ethical objections. Id.”
199. Id.
200. U.S. FOOD & DRUG ADMIN., CTR. FOR VETERINARY MED., FDA
Announces Plant and Animal Biotechnology Innovation Action Plan, U.S. FOOD
&
DRUG
ADMIN.
(updated
Nov.
29,
2018),
https://www.fda.gov/AnimalVeterinary/NewsEvents/CVMUpdates/ucm624490.
htm.
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VIP.201 Eligible developers will have the opportunity to interact
with the Center for Veterinary Medicine review team, receive
hands-on assistance throughout the review process, and obtain
additional review process benefits such as alternative data
options.202 This collaboration between the agency and developers
can increase the predictability of the regulatory pathway,
facilitate a lower number of review cycles, and reduce the overall
time for approval.203 Indeed, the groundbreaking VIP is an
example of the FDA moving towards a participatory approach
regulating new biotechnology products. Through eliciting public
response, working with developers who promote public welfare
with biotechnologies, and assisting developers in managing the
risks of their product applications at an earlier stage, the FDA
is better able to align public values and needs, facilitate
innovation, and create a targeted, flexible review framework for
genome-edited animals.
iv. Setting up a Single Point of Entry
Coupled with adopting the RRI principles, the White House
could also update the Coordinated Framework with a “single
point of entry” for product developers. The National Academies
of Sciences, Engineering, Medicine proposes in its report the
following framework:
Potential product developers and interested parties would
begin by going to an entry point and providing characteristics of
the intended product and its use pattern. If the product does not
fall under a federal statute, the developer would be notified that
the product is not federally regulated. If the product is regulated,
the appropriate agency or agencies would be identified for the
developer. An evaluation of the product’s familiarity to
201. U.S. FOOD & DRUG ADMIN., VIP: Veterinary Innovation Program for
Certain New Animal Drug Applications for Intentionally Altered Genomic DNA
in Animals and Animal Cell, Tissues, and Cell- or Tissue-Based Products
(updated
Oct.
30,
2018),
https://www.fda.gov/AnimalVeterinary/DevelopmentApprovalProcess/Biotechn
ologyProductsatCVMAnimalsandAnimalFood/AnimalswithIntentionalGenomi
cAlterations/ucm620835.htm.
202. Id.
203. Id. The FDA plans to publish guidance documents this year to clarify
its intended oversight processes and clear criteria and data requirements in
evaluating new animal biotechnology products. See Jay Sjerven, F.D.A. Unveils
Plan to Help Guide Innovation in Biotechnology, FOOD BUS. NEWS (Nov. 7,
2018),
https://www.foodbusinessnews.net/articles/12835-fda-unveils-plan-tohelp-guide-innovation-in-biotechnology.
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regulatory agencies and its complexity in terms of risk analyses
as compared to existing biotechnology products would be
ascertained []. Depending on the product’s familiarity and the
complexity of its risk analysis, a different set of risk-analysis
processes would be employed . . . .204
Under a single point of entry, developers can “evaluate
whether the intended use of the product is regulated under a
given statute” instead of window-shopping for regulatory
approval from different agencies.205 A new office could also be set
up to facilitate inter-agency consultations where the risks of a
new product are uncertain and to set future regulatory
directions for biotechnologies.206 This framework would provide
an “accessible public face for the regulatory system” for product
developers, add certainty to the current regulatory system, and
ensure no new products fall outside of the regulatory
framework.207
CONCLUSION
Existing regulatory structures for genome-edited products
with technologies like CRISPR-Cas9 cannot keep up with the
development of biotechnologies. A case in point is the FDA’s
guidance #187 that attempts to extend its jurisdiction of
genome-edited animals to intentionally altered genomic DNAs,
although existing statues do not allow it to do so. The FDA
erroneously interpreted genomic DNA edited with CRISPR-like
technologies as a new animal drug under the FD & C Act, which
was not conceived to cover genome-altered animals when it was
first passed by Congress. The FDA overlooked the product- and
risk-based approach set under the current Coordinated
Framework and adopted a process-based approach that opposes
the regulatory and scientific consensus. The FDA also
circumvented the notice-and-comment rulemaking process by
204. NAT’L ACAD. OF SCI., ENG’G, AND MED., supra note 68, at 9.
205. Id. at 142, 174–75 (“To enable effective regulation of the safe use of
future biotechnology products, it would be beneficial to have a single point of
entry into the regulatory system with a decision-making structure aimed to
assess and manage product risk, to direct products to their appropriate
regulatory agencies, and to increase transparency for developers and society.”).
206. See Peck, supra note131, at 335–36 (“[T]he office would serve as a
resource for the regulators and the public by monitoring and compiling
information about approvals . . . agency procedures, and inter-agency
consultations.”).
207. NAT’L ACAD. OF SCI., ENG’G, AND MED., supra note 68, at 141–43.
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instead issuing a guidance document exempted from the APA
procedural requirements, despite its practically binding legal
effects. Consequently, this guidance has made the future
regulatory landscape regarding genome-edited animals
uncertain and could potentially stifle public confidence and
scientific innovation that would bring benefits to the
environment and human health. Though agencies may construe
the guide-RNA/Cas9 construct inserted into the animal’s
genome as a new animal drug, a veterinary biologic, or a
pesticide and extend their oversight of the construct under
relevant existing statutes, the current structure will handicap
future biotechnology development.
More could be done, and a new regulatory approach must be
introduced. The White House should update the Coordinated
Framework with a “single point of entry” and encourage the
agencies to move towards RRI that fosters responsible
innovation which aligns with public values and expectations.
The FDA’s proposed VIP is an illustration that an agency could
move towards a more cautious, nuanced direction when facing
the unknown and towards a participatory framework that
balances innovation, oversight, and public interest.
Last but not least, regulatory agencies must have open
communication with the public. More open debates are needed
to clarify policy objectives regarding new biotechnologies. The
public should be able to participate in discussions that
determine what constitutes harm, what level of risk is
acceptable, and who should bear the risk. Agencies must ensure
that they gather information from all interested parties and
incorporate their opinions into the respective rulemaking
processes. Most importantly, agency rules must articulate clear
standards for any regulatory approach, providing certainty for
the public and developers of new technologies.
What is the right regulatory approach towards emerging
biotechnologies? RRI might be a solution, but the inquiry should
not stop there. CRISPR-Cas9 democratizes scientific
advancement, and regulation should not be the impediment to
scientific progress. While some level of oversight is required, the
bottom line is that we need the right amount of regulation and
an approach towards CRISPR-like technologies that will keep
genome research vibrant, maintain the U.S. competitive edge
and leadership position, and ensure our present citizens can
receive the benefits that CRISPR-like technologies provide.

